Article

GRF presents Catalyst Award to philanthropists at annual gala

Glaucoma Research Foundation (GRF) honored leaders in areas of philanthropy, business, and medicine who have been instrumental in “developing a cure for glaucoma” during Thursday night’s Glaucoma 360 annual Gala.

San Francisco-Glaucoma Research Foundation (GRF) honored leaders in areas of philanthropy, business, and medicine who have been instrumental in “developing a cure for glaucoma” during Thursday night’s Glaucoma 360 annual Gala.

GRF presented The Catalyst Award, the organization’s highest honor; the Visionary Award, and the President’s Award.

Charlot and Dennis Singleton (Photo courtesy of Glaucoma Research Foundation)Charlot and Dennis Singleton of Atherton, CA, received The Catalyst Award in recognition of their outstanding leadership and philanthropic contributions to medicine and education.

“Dennis has served on our board of directors for 18 years,” said Thomas Brunner, president and CEO of GRF. “He and Charlot give generously to support our mission, as well as many other organizations. We are thrilled to recognize both of them for their extraordinary philanthropy and advocacy.”

First to use ALT 

James B. Wise, MD (Photo courtesy of Glaucoma Research Foundation)

James B. Wise, MD, of Glaucoma and Laser Surgery Associates in Oklahoma City, was presented with The Visionary Award for his many contributions to the field of ophthalmology, in particular the development of argon laser trabeculoplasty (ALT), a laser procedure for the treatment of open-angle glaucoma.

“Jim was the first to use ALT successfully more than 40 years ago and since then it has proven to be an important tool in the management of glaucoma,” Brunner pointed out. “It is wonderful to honor Jim for his innovation that has helped countless patients preserve their vision as well as his continued and generous investment in our research programs.”

 

Masashi Oka (Photo courtesy of Glaucoma Research Foundation)The recipient of the President’s Award was Masashi Oka, executive chairman emeritus for MUFG Union Bank and special advisor to the president and CEO of The Bank of Tokyo-Mitsubishi UFJ. Oka was honored for his efforts in generating support for the Glaucoma Research Foundation and in recognition of his involvement in many community organizations in the City of San Francisco and Northern California.

“Union Bank and Mr. Oka have been great partners with GRF for many years,” Brunner added. “We are so pleased to have an opportunity to honor him for his involvement and support.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.